Bookmarks (11) clear filters

Summary List PlacementHello, Today in healthcare news: The CDC outlines the benefits of double-masking, WHO experts recommend AstraZeneca's shot for all adults, and the pandemic's toll on travel nurses. CDC: Double masks and tightly fitted single masks can reduce COVID-19 transmission by up to 96.4% Double masking has become a trend, but until now there hasn't been much evidence it works. A CDC study...

Summary List PlacementMillions of people across the West have already been given the first dose of a COVID-19 vaccine and up to to 6 billion more doses could be manufactured in 2021, according to industry tracker PharmSource – provided the companies mass-producing shots can find enough employees. Companies manufacturing COVID-19 vaccines are struggling to find enough staff to meet their output goals and have...

Summary List PlacementAn 82-year-old man was the first person to receive the COVID-19 vaccine developed by AstraZeneca and Oxford University since the UK began its rollout, the country's National Health Service said Monday. Brian Pinker, a dialysis patient in Oxford, England, who has kidney disease, got the shot at 7:30 a.m. GMT, or 2:30 a.m. ET, at Oxford University Hospital, the NHS said in...

Summary List PlacementHealth officials in India on Sunday approved two COVID-19 vaccines, including one made by AstraZeneca, for emergency use.  "A decisive turning point to strengthen a spirited fight," India's prime minister, Narendra Modi, said on Twitter. The drugs controller general of India approved a local drug made by Bharat Biotech, along with the vaccine developed by AstraZeneca and Oxford University, according to officials...

Summary List PlacementFollowing months of testing, a coronavirus vaccine created by Oxford-AstraZeneca has been authorized for emergency use by the United Kingdom. The vaccine was designed early on in the pandemic, and trials on it began in April. It's the second vaccine, after Pfizer BioNTech's, to be authorized in the UK.  The vaccine was approved under Regulation 174 of the Human Medicine Regulations 2012,...

Summary List PlacementEarly on Monday, AstraZeneca and the University of Oxford announced preliminary results from a trial of their coronavirus vaccine. It should have been a moment of triumph. They said the vaccine was 70% effective, on average, at preventing COVID-19, the disease caused by the new coronavirus that's swept the world. That surpassed standards that some regulators have set for approval, though it...

Summary List Placement Pharmaceutical company AstraZeneca received some long-awaited good news on Monday: The company's coronavirus vaccine, developed in partnership with the University of Oxford, was found to be 70% effective, on average, in late-stage clinical trials with more than 20,000 volunteers in the UK and Brazil. The results varied depending on the dosage.  Nearly 9,000 volunteers received two full doses at least one...

Summary List Placement The UK government hopes that a coronavirus vaccine will be available by December, say reports. England's deputy chief medical officer Professor Jonathan Van-Tam, this week told members of Parliament that the vaccine being developed at Oxford University with pharmaceutical company AstraZeneca could be available to high-priority groups in time for the New Year, according to The Times of London newspaper. He...

Summary List Placement The US clinical trial of AstraZeneca's COVID-19 vaccine will be suspended for the next several days as the US Food and Drug Administration investigates a potential side effect, according to Reuters. Sources told the news agency on Monday that enrollment in the trial was not being reopened "until at least midweek," pending the investigation. The FDA did not immediately respond to...

Hello, Today, we're tuning in to see drugmakers testify before Congress. But in the meantime, here's what's happening in healthcare.  The first human data from AstraZeneca and Oxford's coronavirus vaccine shows an immune response, a positive sign the shot might work Another leading coronavirus vaccine candidate was able to generate immune responses in healthy volunteers, according to results published Monday. It's the first look...

Affluent countries are spending hundreds of millions of dollars to reserve doses of COVID-19 vaccines for their citizens. This means poorer countries may be left waiting months to get enough doses to inoculate their citizens. The US, UK, France, Germany, Italy, and the Netherlands have all reserved doses of AstraZeneca's vaccine, developed by the University of Oxford. A counter effort is underway to ensure...